GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosyntech Inc (OTCPK:BSYI) » Definitions » Cash, Cash Equivalents, Marketable Securities
中文

Biosyntech (Biosyntech) Cash, Cash Equivalents, Marketable Securities

: $1.37 Mil (As of Dec. 2009)
View and export this data going back to 2000. Start your Free Trial

Biosyntech's quarterly cash, cash equivalents, marketable securities declined from Jun. 2009 ($1.49 Mil) to Sep. 2009 ($0.64 Mil) but then increased from Sep. 2009 ($0.64 Mil) to Dec. 2009 ($1.37 Mil).

Biosyntech's annual cash, cash equivalents, marketable securities declined from Mar. 2007 ($10.21 Mil) to Mar. 2008 ($3.57 Mil) but then increased from Mar. 2008 ($3.57 Mil) to Mar. 2009 ($3.90 Mil).


Biosyntech Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Biosyntech's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyntech Annual Data
Trend Mar00 Mar01 Mar02 Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.74 9.41 10.21 3.57 3.90

Biosyntech Quarterly Data
Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 3.90 1.49 0.64 1.37

Biosyntech Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Biosyntech  (OTCPK:BSYI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Biosyntech Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Biosyntech's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyntech (Biosyntech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosyntech Inc (OTCPK:BSYI) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
475 Boulevard Armand-Frappier, Laval, QC, CAN, H7V 4B3
Biosyntech Inc is engaged in developing advanced biotherapeutics thermogels specifically designed for tissue repair and delivery of therapeutic agents. The company's products include BST-CarGel, BST-InPod, BST-DermOn, BST-Ossifil and BST-Ossifix and BST-Disc for intervertebral disc restoration.

Biosyntech (Biosyntech) Headlines

No Headlines